StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)

Close on Nov 17, 2026Market cap $9.75BP/E –Yield –

Madrigal Pharmaceuticals profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Madrigal Pharmaceuticals's profit margin for the twelve months ending Jun 30, 2026 was -25.3%. For fiscal 2025 it was -30.1%, against -258.6% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-30.1%+228.6
FY2024Dec 31, 2024-258.6%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-15.9%+4.0
Q1 FY2026Mar 31, 2026-30.3%+23.0
Q4 FY2025Dec 31, 2025-18.2%+39.3
Q3 FY2025Sep 30, 2025-39.8%+132.3
Q2 FY2025Jun 30, 2025-19.9%+1018.3
Q1 FY2025Mar 31, 2025-53.4%–
Q4 FY2024Dec 31, 2024-57.5%–
Q3 FY2024Sep 30, 2024-172.0%–
Q2 FY2024Jun 30, 2024-1038.2%–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?